Fishman Jay A Ltd. MI increased its position in Zoetis Inc (NYSE:ZTS) by 200.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,338 shares of the company’s stock after buying an additional 10,900 shares during the period. Fishman Jay A Ltd. MI’s holdings in Zoetis were worth $2,036,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of ZTS. Nuveen Asset Management LLC lifted its position in shares of Zoetis by 40,874.9% in the second quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock worth $803,376,000 after buying an additional 7,061,550 shares in the last quarter. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of Zoetis in the second quarter worth about $133,113,000. Bank of New York Mellon Corp lifted its position in shares of Zoetis by 9.5% in the second quarter. Bank of New York Mellon Corp now owns 4,420,261 shares of the company’s stock worth $501,654,000 after buying an additional 383,799 shares in the last quarter. Vanguard Group Inc. raised its position in Zoetis by 1.0% during the second quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock valued at $4,172,526,000 after purchasing an additional 346,167 shares during the period. Finally, Natixis raised its position in Zoetis by 147.1% during the second quarter. Natixis now owns 547,078 shares of the company’s stock valued at $62,088,000 after purchasing an additional 325,661 shares during the period. Institutional investors own 89.95% of the company’s stock.
Shares of NYSE ZTS traded down $3.17 during midday trading on Friday, hitting $117.86. The company’s stock had a trading volume of 3,757,845 shares, compared to its average volume of 2,125,332. The company has a current ratio of 4.17, a quick ratio of 2.87 and a debt-to-equity ratio of 2.74. The business’s 50 day moving average is $125.46 and its two-hundred day moving average is $116.48. Zoetis Inc has a 12-month low of $78.90 and a 12-month high of $130.20. The firm has a market cap of $57.43 billion, a P/E ratio of 37.65, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.58 billion. During the same period in the prior year, the business posted $0.83 earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, analysts predict that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Tuesday, October 22nd will be issued a $0.164 dividend. The ex-dividend date is Monday, October 21st. This represents a $0.66 annualized dividend and a dividend yield of 0.56%. Zoetis’s payout ratio is 21.09%.
In other news, insider Clinton A. Jr. Lewis sold 6,123 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $123.51, for a total value of $756,251.73. Following the sale, the insider now directly owns 44,255 shares in the company, valued at $5,465,935.05. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Roxanne Lagano sold 4,463 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $125.99, for a total value of $562,293.37. Following the completion of the sale, the executive vice president now owns 33,190 shares in the company, valued at $4,181,608.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,332 shares of company stock worth $4,258,182. Company insiders own 0.29% of the company’s stock.
ZTS has been the topic of a number of recent research reports. Craig Hallum upped their price objective on Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Goldman Sachs Group initiated coverage on Zoetis in a research report on Monday, September 9th. They set a “conviction-buy” rating and a $145.00 price objective on the stock. SunTrust Banks upped their price objective on Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research report on Tuesday, August 13th. Stifel Nicolaus set a $140.00 price objective on Zoetis and gave the company a “buy” rating in a research report on Friday, September 13th. Finally, ValuEngine downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Eight research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Zoetis has a consensus rating of “Buy” and a consensus target price of $126.75.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: What is a Roth IRA?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.